Takeda Pharmaceutical Co Ltd
Change company Symbol lookup
Select an option...
TKPHF Takeda Pharmaceutical Co Ltd
QRTEA Qurate Retail Inc
SRRA Sierra Oncology Inc
ICPT Intercept Pharmaceuticals Inc
MO Altria Group Inc
AI C3.ai Inc
INUV Inuvo Inc
PZZA Papa John's International Inc
REVHU Revolution Healthcare Acquisition Corp
DORM Dorman Products Inc
Go


Based in Japan
Company profile

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Price
Delayed
$29.42
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 0 shares is on pace to be much lighter than TKPHF's 10-day average volume of 121,162 shares.

0

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, May 26, 2022
Takeda and Seagen to Highlight ADCETRIS(R) Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS(R) (brentuximab vedotin) plus chemotherapy combination will be...(BusinessWire)

May 11, 2022
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

--- Highest Total Number of Approvals for Takeda in a Fiscal Year Across Japan (4 NMEs), China (3 NMEs), the U.S. (2 NMEs), and Europe (1 NME) --- Robust Free Cash Flow of JPY 943.7 Billion ($7.8B); Net Debt/Adjusted EBITDA of 2.8x (BusinessWire)

April 28, 2022
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases -- CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare...(Globe Newswire)

April 26, 2022
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories

--a^' Vaccine Facility in Singen, Germany, Wins Pharma 4.0 Category for Applying Digital Technologies in Production Process --a^' Recognition Illustrates Takeda's Patient-Centricity Throughout its Manufacturing and Supply Processes (BusinessWire)

April 22, 2022
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY(TM) (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

Takeda (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical...(BusinessWire)

April 18, 2022
Takeda Announces Approval of Nuvaxovid(R) COVID-19 Vaccine for Primary and Booster Immunization in Japan

--a^' Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies --a^' Takeda is manufacturing Nuvaxovid at its Hikari facility and will begin distribution in Japan as soon as...(BusinessWire)

Takeda's TAKHZYRO(R) (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO(R) (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and...(BusinessWire)

April 13, 2022
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027

FinancialNewsMedia.com News Commentary - Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent that it interferes with a person's daily life and activities. These functions...(PR Newswire)

Takeda Announces Completion of Acquisition of Own Shares

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") today provided an update on the status and announced the completion of the acquisition of its own shares, which has been carried out pursuant to the provision of its Articles of...(BusinessWire)

April 12, 2022
Takeda's TAKHZYRO(R) (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)

Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO(R) (lanadelumab) in patients 2 to <12 years of age is complete and has met its...(BusinessWire)

April 05, 2022
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners

--a^' Winners' Discoveries Reveal the Power of the Gut Microbiome --a^' Recipients Receive Unrestricted $200,000 USD Award Takeda (TSE:4502/NYSE:TAK) and the New York Academy of Sciences today announced the winners of the fourth Innovators in...(BusinessWire)

March 28, 2022
Takeda's TAKHZYRO(R) (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

--a^' Approval Based on Results of Global Phase 3 HELP Study(TM), Phase 3 HELP OLE and a Phase 3 Study in Japanese Patients Evaluating the Efficacy and Safety of TAKHZYRO(1) --a^' In a Japan-Specific Phase 3 Study, 41.7% of the Patients Did Not...(BusinessWire)

February 28, 2022
Interim Phase 4 Data Support TAKHZYRO(R) (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

--a^' Interim Patient-Reported Outcomes Showed a Reduction of Monthly Attack Rates in New Users and Showed Sustained Angioedema Control in Established Users Over Twelve-Months Using the Angioedema Control Test (AECT)(1,2,3) (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.